Skip to main content

Table 4 Change in hematology parameters relative to normal range from screening to week 24 — safety analysis set

From: First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes

Parameter, n (%)

 

Placebo (n = 10)

IMCY-0098 dose A (n = 6)

IMCY-0098 dose B (n = 9)

IMCY-0098 dose C (n = 16)

Total (N = 41)

Erythrocytes (10^12/L)

n [1]

10

6

9

16

41

Decrease to low

0

0

4 (44.4)

3 (18.8)

7 (17.1)

Change to normal or no change

10 (100)

6 (100)

5 (55.6)

13 (81.3)

34 (82.9)

Increase to high

0

0

0

0

0

Monocytes (10^9/L)

n [1]

10

6

9

16

41

Decrease to low

0

0

2 (22.2)

0

2 (4.9)

Change to normal or no change

9 (90.0)

6 (100)

6 (66.7)

14 (87.5)

35 (85.4)

Increase to high

1 (10.0)

0

1 (11.1)

2 (12.5)

4 (9.8)

Lymphocytes/leukocytes (%)

n [1]

10

6

9

16

41

Decrease to low

2 (20.0)

0

1 (11.1)

2 (12.5)

5 (12.2)

Change to normal or no change

6 (60.0)

4 (66.7)

7 (77.8)

12 (75.0)

29 (70.7)

Increase to high

2 (20.0)

2 (33.3)

1 (11.1)

2 (12.5)

7 (17.1)

Monocytes/leukocytes (%)

n [1]

10

6

9

16

41

Decrease to low

1 (10.0)

1 (16.7)

0

0

2 (4.9)

Change to normal or no change

8 (80.0)

3 (50.0)

9 (100)

15 (93.8)

35 (85.4)

Increase to high

1 (10.0)

2 (33.3)

0

1 (6.3)

4 (9.8)

Granulocytes/leukocytes (%)

n [1]

0

0

0

1

1

Decrease to low

0

0

0

0

0

Change to normal or no change

0

0

0

1 (100)

1 (100)

Increase to high

0

0

0

0

0

Neutrophile granulocytes (10^9/L)

n [1]

10

6

9

16

41

Decrease to low

1 (10.0)

1 (16.7)

1 (11.1)

1 (6.3)

4 (9.8)

Change to normal or no change

7 (70.0)

5 (83.3)

7 (77.8)

12 (75.0)

31 (75.6)

Increase to high

2 (20.0)

0

1 (11.1)

3 (18.8)

6 (14.6)

Eosinophile granulocytes (10^9/L)

n [1]

10

6

9

16

41

Decrease to low

1 (10.0)

0

0

1 (6.3)

2 (4.9)

Change to normal or no change

8 (80.0)

6 (100)

8 (88.9)

14 (87.5)

36 (87.8)

Increase to high

1 (10.0)

0

1 (11.1)

1 (6.3)

3 (7.3)

Bas. granulocytes (10^9/L)

n [1]

10

6

9

16

41

Decrease to low

0

0

0

0

0

Change to normal or no change

9 (90.0)

4 (66.7)

8 (88.9)

14 (87.5)

35 (85.4)

Increase to high

1 (10.0)

2 (33.3)

1 (11.1)

2 (12.5)

6 (14.6)

Neutrophile granulocytes/leukocytes (%)

n [1]

10

6

9

16

41

Decrease to low

0

0

1 (11.1)

1 (6.3)

2 (4.9)

Change to normal or no change

9 (90.0)

6 (100)

8 (88.9)

13 (81.3)

36 (87.8)

Increase to high

1 (10.0)

0

0

2 (12.5)

3 (7.3)

Neutr. granulocytes/leukocytes (%)

n [1]

0

2

0

1

3

Decrease to low

0

1 (50.0)

0

0

1 (33.3)

Change to normal or no change

0

1 (50.0)

0

1 (100)

2 (66.7)

Increase to high

0

0

0

0

0

Eosinophile granulocytes/leukocytes (%)

n [1]

10

6

9

16

41

Decrease to low

1 (10.0)

0

0

1 (6.3)

2 (4.9)

Change to normal or no change

7 (70.0)

5 (83.3)

9 (100)

14 (87.5)

35 (85.4)

Increase to high

2 (20.0)

1 (16.7)

0

1 (6.3)

4 (9.8)

Eosin. granulocytes/leukocytes (%)

n [1]

0

2

0

1

3

Decrease to low

0

0

0

0

0

Change to normal or no change

0

2 (100)

0

1 (100)

3 (100)

Increase to high

0

0

0

0

0

Basophile granulocytes/leukocytes (%)

n [1]

0

2

0

0

2

Decrease to low

0

0

0

0

0

Change to normal or no change

0

0

0

0

0

Increase to high

0

2 (100)

0

0

2 (100)

Bas. granulocytes/leukocytes (%)

n [1]

10

6

9

16

41

Decrease to low

0

0

0

0

0

Change to normal or no change

10 (100)

5 (83.3)

8 (88.9)

16 (100)

39 (95.1)

Increase to high

0

1 (16.7)

1 (11.1)

0

2 (4.9)

Lymphocytes atypical/leukocytes (%)

n [1]

0

2

0

1

3

Decrease to low

0

0

0

0

0

Change to normal or no change

0

0

0

0

0

Increase to high

0

2 (100)

0

1 (100)

3 (100)

Smudge cells/leukocytes (%)

n [1]

0

2

0

0

2

Decrease to low

0

0

0

0

0

Change to normal or no change

0

2 (100)

0

0

2 (100)

Increase to high

0

0

0

0

0

  1. n [1], subjects with at least one report